The enbrel market research report is one of a series of new reports that provides enbrel market statistics, including enbrel industry global market size, regional shares, competitors with a enbrel market share, detailed enbrel market segments, market trends and opportunities, and any further data you may need to thrive in the enbrel industry. This enbrel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The enbrel market size is expected to see strong growth in the next few years. It will grow to $20,930.9 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to growing use of enbrel in multiple indications, increasing government support for biologics and rheumatoid arthritis (ra) treatment, growing awareness of autoimmune diseases, rising awareness of inflammatory diseases in the general population, increasing availability of biosimilars, promoting awareness of enbrel. Major trends in the forecast period include digital healthcare tools for managing autoimmune diseases, global partnerships between pharmaceutical companies, development of long-acting injectable formulations for better patient compliance, integration of artificial intelligence in drug development for autoimmune diseases, development of alternative delivery systems for biologic drugs.
The growing prevalence of autoimmune conditions is anticipated to fuel the expansion of the Enbrel market. Autoimmune conditions arise when the immune system erroneously attacks the body’s healthy cells and tissues, causing inflammation and damage to various organs. This increasing prevalence is linked to factors such as genetic predisposition, environmental triggers, and lifestyle or immune system behavior changes. The rising number of autoimmune cases boosts the demand for treatments like Enbrel, which manages inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. For example, in August 2022, the National Library of Medicine reported approximately 928 cases of autoimmune conditions associated with COVID-19 vaccination in 2022. Among these, 81.5% (756 cases) were new-onset autoimmune diseases, with symptoms typically appearing eight days post-vaccination. Women accounted for 53.6% of the cases, with a median age of 48. Thus, the growing prevalence of autoimmune conditions is projected to drive the Enbrel market forward.
A significant trend in the Enbrel market involves obtaining regulatory drug approvals to enhance competitive positioning. Drug approval processes involve regulatory authorities assessing and authorizing new drugs for safety, efficacy, and quality based on clinical trial data. For instance, in October 2023, Amgen Inc., a US-based biopharmaceutical company, announced FDA approval for Enbrel to treat children aged two and older with active juvenile psoriatic arthritis (JPsA). This approval underscores the unique attributes of etanercept as a tumor necrosis factor blocker, demonstrated through comprehensive safety and efficacy studies in adults with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and psoriasis. It also includes pharmacokinetic (PK) data supporting its use in pediatric patients with active juvenile idiopathic arthritis (JIA) and psoriasis. The recommended dosage for juvenile PsA (JPsA) is weight-based and administered via weekly subcutaneous injection.
In November 2023, Amazon Web Services Inc. (AWS), a US-based cloud computing company, partnered with Amgen Inc. to enhance production output and expedite global delivery of medications to patients. Through this collaboration, Amgen is utilizing AWS to develop generative AI-based solutions to accelerate the discovery, development, and manufacturing processes for medicines aimed at treating serious illnesses. Amgen Inc. is a US-based producer of Enbrel.
The key copanies operating in the enbrel market is Amgen Inc.
North America was the largest region in the enbrel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in enbrel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the enbrel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Enbrel (generic name: etanercept) is a prescription drug used to manage various autoimmune disorders by suppressing the immune system. This biologic medication functions by blocking tumor necrosis factor (TNF), a substance that contributes to inflammation in conditions like rheumatoid arthritis and psoriasis.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Enbrel is available in several forms, including injectable solutions, prefilled syringes, combination therapies, extended-release formulations, and biosimilars. Injectable solutions are liquid medications administered via injection. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and other related conditions.
The enbrel market consists of sales of monoclonal antibodies, cancer immunotherapy drugs and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The enbrel market size is expected to see strong growth in the next few years. It will grow to $20,930.9 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to growing use of enbrel in multiple indications, increasing government support for biologics and rheumatoid arthritis (ra) treatment, growing awareness of autoimmune diseases, rising awareness of inflammatory diseases in the general population, increasing availability of biosimilars, promoting awareness of enbrel. Major trends in the forecast period include digital healthcare tools for managing autoimmune diseases, global partnerships between pharmaceutical companies, development of long-acting injectable formulations for better patient compliance, integration of artificial intelligence in drug development for autoimmune diseases, development of alternative delivery systems for biologic drugs.
The growing prevalence of autoimmune conditions is anticipated to fuel the expansion of the Enbrel market. Autoimmune conditions arise when the immune system erroneously attacks the body’s healthy cells and tissues, causing inflammation and damage to various organs. This increasing prevalence is linked to factors such as genetic predisposition, environmental triggers, and lifestyle or immune system behavior changes. The rising number of autoimmune cases boosts the demand for treatments like Enbrel, which manages inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. For example, in August 2022, the National Library of Medicine reported approximately 928 cases of autoimmune conditions associated with COVID-19 vaccination in 2022. Among these, 81.5% (756 cases) were new-onset autoimmune diseases, with symptoms typically appearing eight days post-vaccination. Women accounted for 53.6% of the cases, with a median age of 48. Thus, the growing prevalence of autoimmune conditions is projected to drive the Enbrel market forward.
A significant trend in the Enbrel market involves obtaining regulatory drug approvals to enhance competitive positioning. Drug approval processes involve regulatory authorities assessing and authorizing new drugs for safety, efficacy, and quality based on clinical trial data. For instance, in October 2023, Amgen Inc., a US-based biopharmaceutical company, announced FDA approval for Enbrel to treat children aged two and older with active juvenile psoriatic arthritis (JPsA). This approval underscores the unique attributes of etanercept as a tumor necrosis factor blocker, demonstrated through comprehensive safety and efficacy studies in adults with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and psoriasis. It also includes pharmacokinetic (PK) data supporting its use in pediatric patients with active juvenile idiopathic arthritis (JIA) and psoriasis. The recommended dosage for juvenile PsA (JPsA) is weight-based and administered via weekly subcutaneous injection.
In November 2023, Amazon Web Services Inc. (AWS), a US-based cloud computing company, partnered with Amgen Inc. to enhance production output and expedite global delivery of medications to patients. Through this collaboration, Amgen is utilizing AWS to develop generative AI-based solutions to accelerate the discovery, development, and manufacturing processes for medicines aimed at treating serious illnesses. Amgen Inc. is a US-based producer of Enbrel.
The key copanies operating in the enbrel market is Amgen Inc.
North America was the largest region in the enbrel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in enbrel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the enbrel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Enbrel (generic name: etanercept) is a prescription drug used to manage various autoimmune disorders by suppressing the immune system. This biologic medication functions by blocking tumor necrosis factor (TNF), a substance that contributes to inflammation in conditions like rheumatoid arthritis and psoriasis.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Enbrel is available in several forms, including injectable solutions, prefilled syringes, combination therapies, extended-release formulations, and biosimilars. Injectable solutions are liquid medications administered via injection. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and other related conditions.
The enbrel market consists of sales of monoclonal antibodies, cancer immunotherapy drugs and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Enbrel Market Characteristics4. Enbrel Market Trends And Strategies5. Enbrel Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Enbrel Pricing Analysis & Forecasts30. Global Enbrel Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Enbrel Market32. Recent Developments In The Enbrel Market
3. Enbrel Market Biologic Drug Characteristics
6. Global Enbrel Growth Analysis And Strategic Analysis Framework
8. Enbrel Market Segmentation
9. Global Enbrel Epidemiology Of Clinical Indications
10. Enbrel Market Regional And Country Analysis
11. Asia-Pacific Enbrel Market
12. China Enbrel Market
13. India Enbrel Market
14. Japan Enbrel Market
15. Australia Enbrel Market
16. South Korea Enbrel Market
17. Western Europe Enbrel Market
18. UK Enbrel Market
19. Germany Enbrel Market
20. France Enbrel Market
21. Eastern Europe Enbrel Market
22. North America Enbrel Market
23. USA Enbrel Market
24. Canada Enbrel Market
25. South America Enbrel Market
26. Middle East Enbrel Market
27. Africa Enbrel Market
28. Enbrel Market Competitive Landscape And Company Profiles
29. Global Enbrel Market Pipeline Analysis
33. Enbrel Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Enbrel Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on enbrel market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for enbrel ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The enbrel market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Injectable Solution; Prefilled Syringes; Combination Therapy; Extended Release Formulations; Biosimilars2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Rheumatoid Arthritis; Juvenile Idiopathic Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Other Applications
Key Companies Profiled: Amgen Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Amgen Inc.